Philippines FDA Revokes Sanofi’s Product Registration For Dengvaxia; Company Appeals Decision

PhilStar: Sanofi Pasteur appeals Philippines revocation of Dengvaxia’s certificate of product registration
“Pharmaceutical firm Sanofi Pasteur said it has filed for a motion for reconsideration after the country’s Food and Drug Administration permanently revoked the certificates of product registration of dengue vaccine Dengvaxia. FDA Director General Nela Charade Puno on Tuesday said the pharmaceutical company has shown complete disregard of government rules and regulations…” (2/19).

Additional coverage of this story is available from Bloomberg, PhilStar, and Reuters.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.